Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals (Aerie). Through the transaction, Alcon has added the commercial products Rocklatan and Rhopressa, as well as AR-15512, a Phase 3 product candidate for dry eye disease. Read More